Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-963-0100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.82 million
Profitability
Miscellaneous
Employees77
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.25. The biopharmaceutical company earned $29.10 million during the quarter, compared to analyst estimates of $10.32 million. Corbus Pharmaceuticals had a negative return on equity of 139.91% and a negative net margin of 164.68%. View Corbus Pharmaceuticals' Earnings History.
When is Corbus Pharmaceuticals' next earnings date?
What price target have analysts set for CRBP?
7 analysts have issued 12-month target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $18.00 to $38.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $25.8571 in the next year. This suggests a possible upside of 360.9% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.
What is the consensus analysts' recommendation for Corbus Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.
What are Wall Street analysts saying about Corbus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Corbus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. " (8/13/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $24/share is based on an equally weighted composite of: (a) $23.83/share, as a 35x multiple of taxed and diluted $5.60 discounted back to FY19 at 18% (in line with the expected P/E multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $24/share (discounted cash flow analysis using a 15.5% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (5/10/2019)
Has Corbus Pharmaceuticals been receiving favorable news coverage?
News coverage about CRBP stock has trended negative this week, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a news impact score of -2.9 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Corbus Pharmaceuticals.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include G1 Therapeutics (GTHX), Turning Point Therapeutics (TPTX), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Radius Health (RDUS), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), Ra Pharmaceuticals (RARX), BELLUS Health (BLUSF), AnaptysBio (ANAB), Innoviva (INVA), Epizyme (EPZM), Athenex (ATNX), Amneal Pharmaceuticals (AMRX) and Amphastar Pharmaceuticals (AMPH).
What other stocks do shareholders of Corbus Pharmaceuticals own?
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Dr. Yuval Cohen, CEO & Director (Age 44)
- Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 61)
- Dr. Mark A. Tepper, Co-Founder & Consultant (Age 62)
- Dr. Barbara White, Chief Medical Officer (Age 69)
- Ted Jenkins, Sr. Director of Investor Relations & Communications
Who are Corbus Pharmaceuticals' major shareholders?
Corbus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include ETF Managers Group LLC (10.88%), BlackRock Inc. (8.17%), Vanguard Group Inc. (4.78%), D. E. Shaw & Co. Inc. (1.47%), Morgan Stanley (1.44%) and Northern Trust Corp (0.95%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.
Which major investors are selling Corbus Pharmaceuticals stock?
CRBP stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Stephens Inc. AR, Creative Planning, Northern Trust Corp, Alps Advisors Inc., Morgan Stanley, BNP Paribas Arbitrage SA and Ellington Management Group LLC. View Insider Buying and Selling for Corbus Pharmaceuticals.
Which major investors are buying Corbus Pharmaceuticals stock?
CRBP stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, BlackRock Inc., Vanguard Group Inc., AE Wealth Management LLC, Exane Derivatives, Parametric Portfolio Associates LLC, WINTON GROUP Ltd and Price T Rowe Associates Inc. MD. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $5.61.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $362.69 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe.View Additional Information About Corbus Pharmaceuticals.
What is Corbus Pharmaceuticals' official website?
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
